Global Cerebrospinal Fluid Management Devices Market Research Report—Forecast till 2027
$4450 – $6250
Global Cerebrospinal Fluid Management Devices Market is forecasted to exhibit a CAGR of 5.34% from 2020 to 2027 and record USD 2,104.66 Million during review period.
Description
Global Cerebrospinal Fluid Management Devices Market Research Report—Forecast till 2027
Market Synopsis
Global Cerebrospinal Fluid Management Devices Market is forecasted to exhibit a CAGR of 5.34% from 2020 to 2027 and record USD 2,104.66 Million during review period. The global market growth expected to grow due to increasing cases of the prevalence of hydrocephalus & subsequent ventriculomegaly, rising number of cases of hydrocephalus & ventriculomegaly, strategic acquisition, accelerating technology and innovation, and research and development (R&D) in the sector.
The cerebrospinal fluid management devices industry is evaluated to witness a substantial market expansion owing to the rising prevalence rate of neurological disorders such as Parkinson’s disease and Alzheimer’s disease. Furthermore, several public and private companies are emerging innovative technologies in the development of medical devices cerebrospinal fluid management.
Market Segmentation
Global Cerebrospinal Fluid Management Devices Market is classified into the Product, Age Group, and End User.
Based on product, the market has been segmented into shunts & valves, critical care products, dural sealants, and others.
The global cerebrospinal fluid management devices market, based on age group, has been segmented into pediatric, adult, and geriatric. By end-user segment, the market has been classified into hospitals, ambulatory settings, and research and academic institutes.
Regional Analysis
Geographically, the Global Cerebrospinal Fluid Management Devices Market, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the market with the largest share in 2019, due to the presence of medical device manufacturers and a well-established healthcare industry along with expanded adoption of medical professionals. North American cerebrospinal fluid management devices market is driven by the existence of major market players, well established healthcare infrastructure, high alertness, and availability of advanced treatment options. Europe accounts for the second-largest share in the global cerebrospinal fluid management devices market followed by Asia-pacific. The regional market growth is propelled by the biopharmaceutical sector, presence of major manufacturers, government support for research and development, and rising geriatric population.
Asia-Pacific is the largest market due to the rising per capita health spending, rising awareness about hydrocephalus, and growing research funding. The Middle East & Africa cerebrospinal fluid management devices market is further divided into two major regions, namely the Middle East and Africa. In this region, the Middle East would hold a substantial market share over the assessment period owing to the increasing medical tourism, rising R&D spending, emerging healthcare infrastructure, expansion of multinational companies, and increasing favourability and legislative regulations in the region. These factors are estimated to have a positive impact on the Middle East and Africa market over the study period.
Major Players
The key Players in the Global Cerebrospinal Fluid Management Devices Market are Medtronic Plc (Ireland), Möller Medical GmbH (Germany), Argi Grup (Turkey), Natus Medical Incorporated (US), B. Braun Melsungen AG (Germany), Sophia (France), IRRAS AB (Sweden), Longeviti (US), Integra Lifesciences Corporation (US), and others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 17
1.1.1 MARKET SYNOPSIS 17
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 18
2.2 RESEARCH OBJECTIVE 18
2.3 LIST OF ASSUMPTIONS 19
3 RESEARCH METHODOLOGY
3.1 OVERVIEW 20
3.2 DATA MINING 20
3.3 SECONDARY RESEARCH 21
3.4 PRIMARY RESEARCH 22
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 22
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 23
3.5 FORECASTING TECHNIQUES 23
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24
3.6.1 BOTTOM-UP APPROACH 25
3.6.2 TOP-DOWN APPROACH 26
3.7 DATA TRIANGULATION 26
3.8 VALIDATION 27
4 MARKET DYNAMICS
4.1 OVERVIEW 28
4.2 DRIVERS 29
4.2.1 INCREASING PREVALENCE OF HYDROCEPHALUS & SUBSEQUENT RISE IN NUMBER OF SHUNTING PROCEDURES 29
4.2.2 GROWING GERIATRIC POPULATION 29
4.3 RESTRAINTS 30
4.3.1 COMPLICATIONS RELATED TO CSF SHUNT SYSTEMS 30
4.4 OPPORTUNITIES 30
4.4.1 ENTERING DEVELOPING MARKETS 30
4.5 COVID-19 IMPACT ANALYSIS 31
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 32
5.1.1 R&D AND DESIGNING 33
5.1.2 MANUFACTURING 33
5.1.3 DISTRIBUTION 33
5.1.4 MARKETING AND SALES 33
5.1.5 POST-SALES MONITORING 33
5.2 PORTER’S FIVE FORCES MODEL 34
5.2.1 THREAT OF NEW ENTRANTS 34
5.2.2 BARGAINING POWER OF SUPPLIERS 35
5.2.3 BARGAINING POWER OF BUYERS 35
5.2.4 THREAT OF SUBSTITUTES 35
5.2.5 INTENSITY OF RIVALRY 35
6 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
6.1 OVERVIEW 36
6.2 SHUNTS 37
6.3 CRITICAL CARE PRODUCTS 39
6.4 DURAL SEALANTS 40
6.5 OTHERS 40
7 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
7.1 OVERVIEW 41
7.2 PEDIATRIC 42
7.3 ADULT 42
7.4 GERIATRIC 43
8 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
8.1 OVERVIEW 44
8.2 HOSPITALS 45
8.3 AMBULATORY SETTINGS 46
8.4 RESEARCH & ACADEMIC INSTITUTES 46
9 GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY REGION
9.1 OVERVIEW 47
9.2 AMERICAS 48
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.2.1 NORTH AMERICA 51
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.2.1.1 US 54
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.2.1.2 CANADA 56
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.2.2 LATIN AMERICA 59
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3 EUROPE 62
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1 WESTERN EUROPE 65
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1.1 GERMANY 68
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1.2 FRANCE 71
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1.3 REST OF WESTERN EUROPE 73
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1.4 UK 75
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.1.5 ITALY 78
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.2 SPAIN 80
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.3.3 EASTERN EUROPE 83
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER9.4 ASIA-PACIFIC 86
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.1 CHINA 89
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.2 JAPAN 91
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.3 REST OF ASIA PACIFIC 94
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.4 INDIA 96
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.5 SOUTH KOREA 98
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.4.6 AUSTRALIA 101
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 104
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.5.1 MIDDLE EAST 107
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
9.5.2 AFRICA 109
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 112
10.2 COMPETITIVE BENCHMARKING 113
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET 114
10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET 115
10.5 KEY DEVELOPMENT ANALYSIS 115
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 116
10.6.1 ACQUISITION ACTIVITIES 116
10.6.2 EXPANSIONS 116
10.6.3 PRODUCT LAUNCHES 116
10.6.4 FINANCIAL MATRIX 117
10.6.5 R&D EXPENDITURE 117
11 COMPANY PROFILE
11.1 MEDTRONIC PLC 118
11.1.1 COMPANY OVERVIEW 118
11.1.2 FINANCIAL OVERVIEW 119
11.1.3 PRODUCTS/SERVICES OFFERED 119
11.1.4 KEY DEVELOPMENTS 119
11.1.5 SWOT ANALYSIS 120
11.1.6 KEY STRATEGIES 120
11.2 NATUS MEDICAL INCORPORATED 121
11.2.1 COMPANY OVERVIEW 121
11.2.2 FINANCIAL OVERVIEW 121
11.2.3 PRODUCTS/SERVICES OFFERED 122
11.2.4 KEY DEVELOPMENTS 122
11.2.5 SWOT ANALYSIS 122
11.2.6 KEY STRATEGIES 122
11.3 B. BRAUN MELSUNGEN AG 123
11.3.1 COMPANY OVERVIEW 123
11.3.2 FINANCIAL OVERVIEW 123
11.3.3 PRODUCTS/SERVICES OFFERED 124
11.3.4 KEY DEVELOPMENTS 124
11.3.5 SWOT ANALYSIS 125
11.3.6 KEY STRATEGIES 125
11.4 SOPHYSA 126
11.4.1 COMPANY OVERVIEW 126
11.4.2 FINANCIAL OVERVIEW 126
11.4.3 PRODUCTS/SERVICES OFFERED 126
11.4.4 KEY DEVELOPMENTS 126
11.4.5 SWOT ANALYSIS 127
11.4.6 KEY STRATEGIES 127
11.5 IRRAS AB 128
11.5.1 COMPANY OVERVIEW 128
11.5.2 FINANCIAL OVERVIEW 128
11.5.3 PRODUCTS/SERVICES OFFERED 129
11.5.4 KEY DEVELOPMENTS 129
11.5.5 SWOT ANALYSIS 129
11.5.6 KEY STRATEGIES 129
11.6 MÖLLER MEDICAL GMBH 130
11.6.1 COMPANY OVERVIEW 130
11.6.2 FINANCIAL OVERVIEW 130
11.6.3 PRODUCTS/SERVICES OFFERED 130
11.6.4 KEY DEVELOPMENTS 130
11.6.5 SWOT ANALYSIS 130
11.6.6 KEY STRATEGIES 131
11.7 ARGI GRUP 132
11.7.1 COMPANY OVERVIEW 132
11.7.2 FINANCIAL OVERVIEW 132
11.7.3 PRODUCTS/SERVICES OFFERED 132
11.7.4 KEY DEVELOPMENTS 132
11.7.5 SWOT ANALYSIS 133
11.7.6 KEY STRATEGIES 133
11.8 LONGEVITI 134
11.8.1 COMPANY OVERVIEW 134
11.8.2 FINANCIAL OVERVIEW 134
11.8.3 PRODUCTS/SERVICES OFFERED 134
11.8.4 KEY DEVELOPMENTS 134
11.8.5 SWOT ANALYSIS 135
11.8.6 KEY STRATEGIES 135
11.9 INTEGRA LIFESCIENCES CORPORATION 136
11.9.1 COMPANY OVERVIEW 136
11.9.2 FINANCIAL OVERVIEW 136
11.9.3 PRODUCTS/SERVICES OFFERED 137
11.9.4 KEY DEVELOPMENTS 137
11.9.5 SWOT ANALYSIS 137
11.9.6 KEY STRATEGIES 138
11.10 ANUNCIA 139
11.10.1 COMPANY OVERVIEW 139
11.10.2 FINANCIAL OVERVIEW 139
11.10.3 PRODUCTS/SERVICES OFFERED 139
11.10.4 KEY DEVELOPMENTS 139
11.10.5 SWOT ANALYSIS 140
11.10.6 KEY STRATEGIES 140
12 APPENDIX
12.1 REFERENCES 141
12.2 RELATED REPORTS 141
